RxDoctor Payments Data

Ellen Boersma, NP

Nurse Practitioner · Lakeport, CANPI 1265684633

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.3% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,341 and has fallen 71.7% since, to $380 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,177in general payments, 2019–2025

Across 230 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$591
  • AstraZeneca$479
  • GSK$404
  • Daiichi Sankyo Inc.$402
  • Astellas Pharma US Inc$391
  • Johnson & Johnson$390
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$4,72591%
  • Education$4539%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,177 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California →

Medicare billing

Part B allowed, 2024
$235,491
Medicare patients
203
Services billed
11,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Morphine Sulfate ErMorphine Sulfate11$574
Anastrozole20$248
Gabapentin13$108
Prednisone12$40

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Lakeport

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →